552 related articles for article (PubMed ID: 22699202)
1. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
[TBL] [Abstract][Full Text] [Related]
2. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
3. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
[TBL] [Abstract][Full Text] [Related]
4. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
5. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.
Jung W; Jang JY; Kang MJ; Chang YR; Shin YC; Chang J; Kim SW
HPB (Oxford); 2016 Jan; 18(1):57-64. PubMed ID: 26776852
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
7. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
[TBL] [Abstract][Full Text] [Related]
8. The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer.
Crippa S; Salgarello M; Laiti S; Partelli S; Castelli P; Spinelli AE; Tamburrino D; Zamboni G; Falconi M
Dig Liver Dis; 2014 Aug; 46(8):744-9. PubMed ID: 24721105
[TBL] [Abstract][Full Text] [Related]
9. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer.
Kim R; Prithviraj G; Kothari N; Springett G; Malafa M; Hodul P; Kim J; Yue B; Morse B; Mahipal A
Clin Nucl Med; 2015 Nov; 40(11):e501-5. PubMed ID: 26053713
[TBL] [Abstract][Full Text] [Related]
10. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
12. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
Lytras D; Connor S; Bosonnet L; Jayan R; Evans J; Hughes M; Garvey CJ; Ghaneh P; Sutton R; Vinjamuri S; Neoptolemos JP
Dig Surg; 2005; 22(1-2):55-61; discussion 62. PubMed ID: 15838173
[TBL] [Abstract][Full Text] [Related]
14. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
[TBL] [Abstract][Full Text] [Related]
15. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.
Zhang J; Zuo CJ; Jia NY; Wang JH; Hu SP; Yu ZF; Zheng Y; Zhang AY; Feng XY
World J Gastroenterol; 2015 Mar; 21(10):2988-96. PubMed ID: 25780297
[TBL] [Abstract][Full Text] [Related]
16. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
[TBL] [Abstract][Full Text] [Related]
17. [Benefit of PET/CT in the preoperative staging in pancreatic carcinomas].
Kysucan J; Lovecek M; Klos D; Tozzi I; Koranda P; Buriánková E; Neoral C; Havlík R
Rozhl Chir; 2010 Aug; 89(7):433-40. PubMed ID: 20925260
[TBL] [Abstract][Full Text] [Related]
18. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
19. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.
Ariake K; Motoi F; Shimomura H; Mizuma M; Maeda S; Terao C; Tatewaki Y; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Takadate T; Naitoh T; Taki Y; Unno M
J Gastrointest Surg; 2018 Feb; 22(2):279-287. PubMed ID: 29119533
[TBL] [Abstract][Full Text] [Related]
20. Staging accuracy of pancreatic cancer: comparison between non-contrast-enhanced and contrast-enhanced PET/CT.
Yoneyama T; Tateishi U; Endo I; Inoue T
Eur J Radiol; 2014 Oct; 83(10):1734-9. PubMed ID: 25043494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
